Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O'Connor CM, Massie BM. Teerlink JR, et al. Among authors: massie bm. Drug Saf. 2012 Mar 1;35(3):233-44. doi: 10.2165/11594680-000000000-00000. Drug Saf. 2012. PMID: 22339573 Clinical Trial.
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
Metra M, O'Connor CM, Davison BA, Cleland JG, Ponikowski P, Teerlink JR, Voors AA, Givertz MM, Mansoor GA, Bloomfield DM, Jia G, DeLucca P, Massie B, Dittrich H, Cotter G. Metra M, et al. Eur Heart J. 2011 Jun;32(12):1519-34. doi: 10.1093/eurheartj/ehr042. Epub 2011 Mar 8. Eur Heart J. 2011. PMID: 21388992 Clinical Trial.
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Massie BM, et al. N Engl J Med. 2010 Oct 7;363(15):1419-28. doi: 10.1056/NEJMoa0912613. N Engl J Med. 2010. PMID: 20925544 Free article. Clinical Trial.
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Voors AA, et al. Among authors: massie bm. J Am Coll Cardiol. 2011 May 10;57(19):1899-907. doi: 10.1016/j.jacc.2010.11.057. J Am Coll Cardiol. 2011. PMID: 21545947 Free article. Clinical Trial.
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
Davison BA, Metra M, Cotter G, Massie BM, Cleland JGF, Dittrich HC, Edwards C, Filippatos G, Givertz MM, Greenberg B, Ponikowski P, Voors AA, O'Connor CM, Teerlink JR; PROTECT and RELAX-AHF Executive Committees. Davison BA, et al. Among authors: massie bm. JACC Heart Fail. 2015 May;3(5):395-403. doi: 10.1016/j.jchf.2015.01.007. JACC Heart Fail. 2015. PMID: 25951761 Free article. Clinical Trial.
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality.
Davison BA, Metra M, Senger S, Edwards C, Milo O, Bloomfield DM, Cleland JG, Dittrich HC, Givertz MM, O'Connor CM, Massie BM, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Davison BA, et al. Among authors: massie bm. Eur J Heart Fail. 2016 Aug;18(8):1041-50. doi: 10.1002/ejhf.540. Epub 2016 Apr 25. Eur J Heart Fail. 2016. PMID: 27114058 Free article.
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
Biegus J, Hillege HL, Postmus D, Valente MA, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Massie BM, Metra M, Teerlink JR, Voors AA, O'Connor CM, Ponikowski P. Biegus J, et al. Among authors: massie bm. Eur J Heart Fail. 2016 Jul;18(7):830-9. doi: 10.1002/ejhf.532. Epub 2016 May 12. Eur J Heart Fail. 2016. PMID: 27170455 Free article.
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B. Carson PE, et al. JACC Heart Fail. 2015 Jun;3(6):429-441. doi: 10.1016/j.jchf.2014.12.017. Epub 2015 May 14. JACC Heart Fail. 2015. PMID: 25982110 Free article.
416 results